Laurus Labs Reports Quarterly Financial Results for Q1 FY27; Consolidated Income Reaches 365.39 Crores
Laurus Labs Limited announced its unaudited financial results for the quarter ended June 30, 2026, providing detailed insights into both consolidated and standalone performance. The company continues to operate in the manufacture and sale of pharmaceuticals, with the results reflecting ongoing strategic activities, including the exercise of employee stock options and movement toward a planned demerger scheme.The unaudited consolidated financial results show robust top-line growth compared to previous quarters, while the standalone results also demonstrated solid revenue generation. The company has allocated 393,001 equity shares of ₹2 each consequent to the exercise of employee stock options under its Employee Stock Option Scheme during the quarter.
Consolidated Financial Performance Summary (Quarter Ended June 30, 2026)
The consolidated results reflect the operations across the Group's subsidiaries and associates. Key figures for the quarter ended June 30, 2026, as well as comparative data are presented below:| Particulars | Qtr ended June 30, 2026 (Unaudited) | Qtr ended March 31, 2026 (Unaudited) | Qtr ended June 30, 2025 (Unaudited) | Year ended March 31, 2026 (Audited) |
|---|---|---|---|---|
| Total Income | 2,035.49 | 1,123.37 | 1,580.00 | 6,167.85 |
| Expenses (Total) | 1,554.13 | 1,462.00 | 1,355.78 | 5,685.97 |
| Profit before Tax | 481.36 | 361.37 | 224.22 | 1,181.88 |
| Total Tax expense | 119.37 | 79.46 | 63.14 | 292.03 |
| Net Profit after tax | 361.99 | 281.91 | 161.08 | 889.85 |
| Total comprehensive income attributable to equity holders of the company | 365.39 | 281.23 | 162.31 | 882.90 |
Standalone Financial Performance Summary (Quarter Ended June 30, 2026)
The unaudited standalone results for Laurus Labs Limited show a focused performance in the pharmaceutical segment.| Particulars | Qtr ended June 30, 2026 (Unaudited) | Qtr ended March 31, 2026 (Unaudited) | Qtr ended June 30, 2025 (Unaudited) | Year ended March 31, 2026 (Audited) |
|---|---|---|---|---|
| Total Income | 1,777.23 | 1,593.39 | 1,454.27 | 6,166.50 |
| Expenses (Total) | 1,389.06 | 1,334.02 | 1,242.83 | 5,172.41 |
| Profit before Tax | 388.17 | 259.37 | 211.44 | 994.09 |
| Total Tax expense | 98.21 | 67.58 | 53.50 | 253.61 |
| Net Profit after tax | 289.96 | 191.79 | 157.94 | 740.48 |
| Total comprehensive income | 288.15 | 196.79 | 157.75 | 743.38 |
Strategic and Operational Updates
The Board of Directors previously approved a Composite Scheme of Arrangement concerning Laurus Synthesis Private Limited (LSP) and Sriam Labs Private Limited (SLP). This scheme involves the demerger of an identified business undertaking from LSP into SLP, alongside the amalgamation of the remaining undertaking of LSP with Laurus Labs Limited. The implementation of this Scheme is pending necessary final approvals and sanctions from the National Company Law Tribunal, Amaravati Bench at Amaravati.The Group's operations include several entities across different geographies, including subsidiaries in the UK (Laurus Holdings Limited), USA (Laurus Generics Inc.), Germany (Laurus Generics GmbH), South Africa (Laurus Generics SA (Pty) Ltd), and India (Sriam Labs Private Limited and Laurus Synthesis Private Limited). The Group also includes associates such as Immunoadoptive Cell Therapy Private Limited and Ethan Energy India Private Limited, and a joint venture with KRKA Pharma Private Limited.
Earlier in the fiscal year, the company made capital contributions into KRKA for its 49% stake during Q4 FY25, and contributed to Kumool Renewables Private Limited as an associate during Q1 FY26.
LAURUSLABS Stock Price Movement
Shares of Laurus Labs Limited are currently edging higher to ₹1578.9 as of 3:09 PM, having climbed ₹10.60 or 0.68% in live trading. The stock sees strong market activity, with 968,096 shares traded during the session so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.